Zynex Inc CEO Thomas Sandgaard joined Steve Darling from Proactive to reflect on the company’s significant achievements in 2024 and its forward-looking plans for 2025. Sandgaard announced that Zynex reached a major milestone of $200 million in revenue while maintaining profitability. He attributed this success to the dedication of the company's employees and the introduction of innovative pain management products, including braces and cold therapy devices.
Sandgaard also discussed the company’s submission of a laser-based pulse oximeter to the FDA. The goal is to commercialize this advanced technology in the second half of 2025. He emphasized the importance of this device, highlighting its superior accuracy across diverse skin tones, which addresses a critical gap in existing medical technologies.
Looking ahead to 2025, Sandgaard expressed confidence in achieving 10–15% revenue growth and doubling EBITDA. These goals are underpinned by Zynex’s continued expansion into new territories and its focus on employee satisfaction, as reflected in multiple workplace awards the company has received.
With a strong foundation of innovation and a clear vision for growth, Zynex is poised for continued success in the medical device industry.
#proactiveinvestors #zynexinc #nasdaq #zyxi #healthcare #q2 #finanacials
#ThomasSandgaard #RevenueMilestone #FDAApproval #MedicalTechnology #Growth2025 #PulseOximeter #PainManagement #ProactiveNews #HealthcareInnovation#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
